Rochester,NY 7/9/2009 1:24:32 AM
Afternoon Movers - MSHL - Marshall Edwards, Inc.'s Arrangements for Data Analysis of the Ovature Trial - Sourced WhisperFromWallStreet.com
Marshall Edwards Inc.
Afternoon Movers - MSHL - Marshall Edwards, Inc.'s Arrangements for Data Analysis of the Ovature Trial - Sourced WhisperFromWallStreet.com
http://whisperfromwallstreet.com is a FREE award winning newsletter that specializes in sending alerts to our subscribers on stocks we think are going to run, why we think so, as well as teaching you how to become a better trader. We scan hundreds of stocks a day to find those that meet our criteria and when we find one, we send you an alert. We have sent out 40 alerts so far in 2009 with an average price gain of over 80%. Please join risk free and see for yourself.
Sign up for our FREE alerts at WhisperfromWallStreet.com
---
Marshall Edwards Inc. MSHL
After Hours: 1.04 0.34 (48.57%) 2:01pm ET
The Independent Data Monitoring Committee (IDMC) created to oversee the conduct of the Phase III OVArian TUmor REsponse (OVATURE) Trial, which convened during the recent Annual Meeting of the American Society of Clinical Oncology, considered the data accumulated to date and reviewed the arrangements announced by the Company for early termination of patient enrollment into the study.
The IDMC reviewed available unblinded data from 117 subjects and noted that, at the time of termination of recruitment, 142 subjects had been randomized to the study.
The IDMC supported the Company's decision to close the study to accrual, and, in a review of the available safety data, the IDMC confirmed that there were no safety concerns with phenoxodiol in these subjects. Consistent with the IDMC charter, the Company will convene an expert committee to review the IDMC recommendations including those with respect to the disposition of subjects remaining in the OVATURE study.
About
Marshall Edwards, Inc., a developmental stage pharmaceutical company, engages in the development and commercialization of drugs for the treatment of cancer. The company involves in the clinical development of a drug candidate called phenoxodiol, which is undergoing a pivotal Phase III study in combination with carboplatin in women with platinum-resistant ovarian cancer; in Phase I study for use in squamous cell carcinoma of the cervix, vagina, and vulva; and in Phase II clinical trials for the treatment in men with early stage disease. It is also developing two other anti-cancer compounds, including triphendiol, for pancreatic and bile duct cancer and has completed two Phase I human clinical trial; and NV-143, which is targeted for the treatment of melanoma, glioma, prostate, ovarian, and breast and lung cancer and is in the pre-clinical testing stage. The company was founded in 2000 and is based in North Ryde, Australia. Marshall Edwards, Inc. is a subsidiary of Novogen Limited.
Last Trade: 1.0499
Day's Range: 0.77 - 1.3594
52wk Range: 0.25 - 3.32
Volume: 1,007,723
---
Here are a few alerts our WhisperfromWallStreet.com subscribers enjoyed.
SPNG 1000%
AMNG 241%
RKBD 300%
UTRM 169%
TLLE 266%
Sign up to receive free stock alerts
---
Disclaimer: Full disclaimer at http://whisperfromwallstreet.com/disclaimer.php
WhisperfromWallStreet.com (WFWS) based upon information believed to be reliable herein prepared all material. The information contained herein is not guaranteed by WFWS to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. WFWS is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on http://www.whisperfromwallstreet.com or mentioned herein. WFWS may have been compensated with shares or with cash from third party shareholders or the company on behalf of one or more of the companies mentioned in this opinion.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and WFWS undertakes no obligation to update such statements.
This is not a solicitation to buy or sell any securities. WhisperfromWallStreet.com, nor any of its affiliates are not registered investment advisors or a broker dealers. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.
CONTACT: WhisperFromWallStreet.com
